Építés alatt – nem éles oldal
Belépés
VisszavonvaNo phase

Waitlist-Control Trial of Smartphone CBT for Major Depressive Disorder (MDD)

Megadott ok: Trial not initiated

Key facts

Where
Boston, Egyesült ÁllamokSee the site

Where in Egyesült Államok

  • Massachusetts General HospitalBoston, Egyesült ÁllamokNo longer taking part

Trial details

Who runs it
Massachusetts General Hospital
Trial code
NCT04594616
Record updated
2025. május 26.
Original description
The investigators are testing the efficacy of Smartphone-delivered cognitive behavioral therapy (CBT) treatment for major depressive disorder (MDD). The investigators hypothesize that participants receiving app-CBT will have greater improvement in SIGH-D scores than those in the waitlist condition at treatment endpoint (week 8).Read full original descriptionShow less

Smartphone Cognitive Behavioral Therapy for Major Depressive Disorder: A Randomized, Waitlist-control Trial

The investigators are testing the efficacy of Smartphone-delivered cognitive behavioral therapy (CBT) treatment for major depressive disorder (MDD). The investigators hypothesize that participants receiving app-CBT will have greater improvement in SIGH-D scores than those in the waitlist condition at treatment endpoint (week 8).

Inclusion: At least 18 years of age; Current diagnosis of primary DSM-5 MDD, based on MINI; Currently living in the United States.

Exclusion: Psychotropic medication changes within 2 months prior to enrollment (Participants taking psychotropic medication must have been on a stable dose for at least 2 months prior to enrollment and not change medication during study period); Concurrent psychological treatment; Current severe substance use disorder; Lifetime bipolar disorder or psychosis; Past participation in ≥ 4 sessions of CBT for depression; Acute, active suicidal ideation as indicated by clinical judgment and/or a score ≥ 2 on the suicidal ideation subscale of the C-SSRS; Does not own a supported mobile Smartphone with a data plan; Lack of technology literacy that would interfere with ability to engage with smartphone treatment.

ClinicalTrials.gov NCT04594616